Literature DB >> 32783700

Product of natural evolution (SARS, MERS, and SARS-CoV-2); deadly diseases, from SARS to SARS-CoV-2.

Mohamad Hesam Shahrajabian1, Wenli Sun1, Qi Cheng1,2,3.   

Abstract

SARS-CoV-2, the virus causing COVID-19, is a single-stranded RNA virus belonging to the order Nidovirales, family Coronaviridae, and subfamily Coronavirinae. SARS-CoV-2 entry to cellsis initiated by the binding of the viral spike protein (S) to its cellular receptor. The roles of S protein in receptor binding and membrane fusion makes it a prominent target for vaccine development. SARS-CoV-2 genome sequence analysis has shown that this virus belongs to the beta-coronavirus genus, which includes Bat SARS-like coronavirus, SARS-CoV and MERS-CoV. A vaccine should induce a balanced immune response to elicit protective immunity. In this review, we compare and contrast these three important CoV diseases and how they inform on vaccine development.

Entities:  

Keywords:  MERS; SARS; SARS-CoV-2; coronaviruses; emerging diseases; pneumonia

Mesh：

Substances：

Year:  2020        PMID： 32783700      PMCID： PMC7872062          DOI： 10.1080/21645515.2020.1797369

Source DB:  PubMed          Journal:  Hum Vaccin Immunother        ISSN： 2164-5515            Impact factor:   3.452


  334 in total

1.  Antibody-dependent enhancement of SARS coronavirus infection and its role in the pathogenesis of SARS.

Authors:  M S Yip; H L Leung; P H Li; C Y Cheung; I Dutry; D Li; M Daëron; R Bruzzone; J Sm Peiris; M Jaume
Journal:  Hong Kong Med J       Date:  2016-06       Impact factor: 2.227

2.  Immunization with an attenuated severe acute respiratory syndrome coronavirus deleted in E protein protects against lethal respiratory disease.

Authors:  Jason Netland; Marta L DeDiego; Jincun Zhao; Craig Fett; Enrique Álvarez; José L Nieto-Torres; Luis Enjuanes; Stanley Perlman
Journal:  Virology       Date:  2010-01-27       Impact factor: 3.616

3.  Adaptive evolution influences the infectious dose of MERS-CoV necessary to achieve severe respiratory disease.

Authors:  Madeline G Douglas; Jacob F Kocher; Trevor Scobey; Ralph S Baric; Adam S Cockrell
Journal:  Virology       Date:  2017-12-23       Impact factor: 3.616

4.  A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster.

Authors:  Jasper Fuk-Woo Chan; Shuofeng Yuan; Kin-Hang Kok; Kelvin Kai-Wang To; Hin Chu; Jin Yang; Fanfan Xing; Jieling Liu; Cyril Chik-Yan Yip; Rosana Wing-Shan Poon; Hoi-Wah Tsoi; Simon Kam-Fai Lo; Kwok-Hung Chan; Vincent Kwok-Man Poon; Wan-Mui Chan; Jonathan Daniel Ip; Jian-Piao Cai; Vincent Chi-Chung Cheng; Honglin Chen; Christopher Kim-Ming Hui; Kwok-Yung Yuen
Journal:  Lancet       Date:  2020-01-24       Impact factor: 79.321

5.  The effect of control strategies to reduce social mixing on outcomes of the COVID-19 epidemic in Wuhan, China: a modelling study.

Authors:  Kiesha Prem; Yang Liu; Timothy W Russell; Adam J Kucharski; Rosalind M Eggo; Nicholas Davies; Mark Jit; Petra Klepac
Journal:  Lancet Public Health       Date:  2020-03-25

Review 6.  Accessory proteins of SARS-CoV and other coronaviruses.

Authors:  Ding Xiang Liu; To Sing Fung; Kelvin Kian-Long Chong; Aditi Shukla; Rolf Hilgenfeld
Journal:  Antiviral Res       Date:  2014-07-01       Impact factor: 5.970

7.  Immunogenicity of an adenoviral-based Middle East Respiratory Syndrome coronavirus vaccine in BALB/c mice.

Authors:  Eun Kim; Kaori Okada; Tom Kenniston; V Stalin Raj; Mohd M AlHajri; Elmoubasher A B A Farag; Farhoud AlHajri; Albert D M E Osterhaus; Bart L Haagmans; Andrea Gambotto
Journal:  Vaccine       Date:  2014-09-03       Impact factor: 3.641

8.  Simulating the SARS outbreak in Beijing with limited data.

Authors:  Wendi Wang; Shigui Ruan
Journal:  J Theor Biol       Date:  2004-04-07       Impact factor: 2.691

9.  Antibody Responses to SARS-CoV-2 in Patients With Novel Coronavirus Disease 2019.

Authors:  Juanjuan Zhao; Quan Yuan; Haiyan Wang; Wei Liu; Xuejiao Liao; Yingying Su; Xin Wang; Jing Yuan; Tingdong Li; Jinxiu Li; Shen Qian; Congming Hong; Fuxiang Wang; Yingxia Liu; Zhaoqin Wang; Qing He; Zhiyong Li; Bin He; Tianying Zhang; Yang Fu; Shengxiang Ge; Lei Liu; Jun Zhang; Ningshao Xia; Zheng Zhang
Journal:  Clin Infect Dis       Date:  2020-11-19       Impact factor: 9.079

10.  A recombinant baculovirus-expressed S glycoprotein vaccine elicits high titers of SARS-associated coronavirus (SARS-CoV) neutralizing antibodies in mice.

Authors:  Zhimin Zhou; Penny Post; Rick Chubet; Katherine Holtz; Clifton McPherson; Martin Petric; Manon Cox
Journal:  Vaccine       Date:  2006-02-09       Impact factor: 3.641
View more
  2 in total

Review 1.  Severe acute respiratory syndrome coronavirus 2 infection: Role of interleukin-6 and the inflammatory cascade.

Authors:  Mohaddeseh Bahmani; Rojin Chegini; Elham Ghanbari; Elham Sheykhsaran; Parisa Shiri Aghbash; Hamed Ebrahimzadeh Leylabadlo; Ehsan Moradian; Amir Masoud Kazemzadeh Houjaghan; Hossein Bannazadeh Baghi
Journal:  World J Virol       Date:  2022-05-25

2.  Low SARS-CoV-2 viral load among vaccinated individuals infected with Delta B.1.617.2 and Omicron BA.1.1.529 but not with Omicron BA.1.1 and BA.2 variants.

Authors:  Sivaprakasam T Selvavinayagam; Yean Kong Yong; Narcisse Joseph; Kannan Hemashree; Hong Yien Tan; Ying Zhang; Manivannan Rajeshkumar; Anandhazhvar Kumaresan; Raghu Kalpana; Vasudevan Kalaivani; Ayyagari Venkata Devi Monika; Suvaiyarasan Suvaithenamudhan; Meganathan Kannan; Amudhan Murugesan; Krishnasamy Narayanasamy; Sampath Palani; Marie Larsson; Esaki M Shankar; Sivadoss Raju
Journal:  Front Public Health       Date:  2022-09-20
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.